[go: up one dir, main page]

SI2350279T1 - Postopek za zdravljenje očesnih motenj - Google Patents

Postopek za zdravljenje očesnih motenj

Info

Publication number
SI2350279T1
SI2350279T1 SI200931373T SI200931373T SI2350279T1 SI 2350279 T1 SI2350279 T1 SI 2350279T1 SI 200931373 T SI200931373 T SI 200931373T SI 200931373 T SI200931373 T SI 200931373T SI 2350279 T1 SI2350279 T1 SI 2350279T1
Authority
SI
Slovenia
Prior art keywords
methods
eye disorders
treating eye
treating
disorders
Prior art date
Application number
SI200931373T
Other languages
English (en)
Inventor
Elena Feinstein
Evgenia Alpert
Igor Mett
Amir Bar-Ilan
Igor Spivak
Hagar Kalinski
Netanja Slager
Original Assignee
Quark Pharmaceuticals, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Quark Pharmaceuticals, Inc. filed Critical Quark Pharmaceuticals, Inc.
Publication of SI2350279T1 publication Critical patent/SI2350279T1/sl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/711—Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI200931373T 2008-10-22 2009-10-22 Postopek za zdravljenje očesnih motenj SI2350279T1 (sl)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US19699508P 2008-10-22 2008-10-22
US19893108P 2008-11-11 2008-11-11
IL2009000179 2009-02-15
PCT/US2009/061570 WO2010048352A2 (en) 2008-10-22 2009-10-22 Methods for treating eye disorders
EP09748890.2A EP2350279B1 (en) 2008-10-22 2009-10-22 Methods for treating eye disorders

Publications (1)

Publication Number Publication Date
SI2350279T1 true SI2350279T1 (sl) 2016-04-29

Family

ID=54839547

Family Applications (1)

Application Number Title Priority Date Filing Date
SI200931373T SI2350279T1 (sl) 2008-10-22 2009-10-22 Postopek za zdravljenje očesnih motenj

Country Status (15)

Country Link
US (4) US8765931B2 (sl)
EP (1) EP2350279B1 (sl)
JP (1) JP5592892B2 (sl)
KR (1) KR101672563B1 (sl)
CN (3) CN102994500B (sl)
AU (1) AU2009308380B2 (sl)
CA (2) CA2738957A1 (sl)
DK (1) DK2350279T3 (sl)
EA (1) EA022418B1 (sl)
ES (1) ES2563984T3 (sl)
IL (1) IL212986A (sl)
NZ (1) NZ591391A (sl)
PL (1) PL2350279T3 (sl)
SI (1) SI2350279T1 (sl)
WO (1) WO2010048352A2 (sl)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2293800B1 (en) 2008-06-06 2016-10-05 Quark Pharmaceuticals, Inc. Compositions and methods for treatment of ear disorders
KR101672563B1 (ko) * 2008-10-22 2016-11-03 쿠아크 파마수티칼스 인코퍼레이티드 안질환을 치료하는 방법
CA2744987C (en) 2008-12-02 2018-01-16 Chiralgen, Ltd. Method for the synthesis of phosphorus atom modified nucleic acids
CA2767253A1 (en) 2009-07-06 2011-01-13 Ontorii, Inc. Novel nucleic acid prodrugs and methods of use thereof
CA2770104C (en) * 2009-08-11 2019-03-19 Opko Curna, Llc Treatment of adiponectin (adipoq) related diseases by inhibition of natural antisense transcript to an adiponectin (adipoq)
NZ599237A (en) 2009-11-26 2014-03-28 Quark Pharmaceuticals Inc Sirna compounds comprising terminal substitutions
WO2012006083A2 (en) * 2010-07-09 2012-01-12 University Of Florida Research Foundation, Inc. Targeted receptor-mediated sirna
WO2012039448A1 (ja) 2010-09-24 2012-03-29 株式会社キラルジェン 不斉補助基
WO2013012758A1 (en) 2011-07-19 2013-01-24 Ontorii, Inc. Methods for the synthesis of functionalized nucleic acids
AU2012332517B9 (en) 2011-11-03 2017-08-10 Quark Pharmaceuticals, Inc. Methods and compositions for neuroprotection
WO2013070821A1 (en) 2011-11-08 2013-05-16 Quark Pharmaceuticals, Inc. Methods and compositions for treating diseases, disorders or injury of the nervous system
KR20140109430A (ko) * 2012-01-04 2014-09-15 쿠아크 파마수티칼스 인코퍼레이티드 Casp2에 대한 이중-가닥 rna 화합물 및 그 용도
CN104684923B (zh) 2012-07-13 2018-09-28 株式会社新日本科学 手性核酸佐剂
KR102712879B1 (ko) 2012-07-13 2024-10-04 웨이브 라이프 사이언시스 리미티드 키랄 제어
JP6268157B2 (ja) 2012-07-13 2018-01-24 株式会社Ｗａｖｅ Ｌｉｆｅ Ｓｃｉｅｎｃｅｓ Ｊａｐａｎ 不斉補助基
BR112015004747A2 (pt) 2012-09-12 2017-11-21 Quark Pharmaceuticals Inc moléculas oligonucleotídicas de fita dupla para p53 e métodos de uso das mesmas
EP2895608B1 (en) 2012-09-12 2018-12-05 Quark Pharmaceuticals, Inc. Double-stranded oligonucleotide molecules to p53 and methods of use thereof
JP6353365B2 (ja) * 2012-09-27 2018-07-04 千寿製薬株式会社 水性液剤
CN105209619B (zh) * 2013-03-11 2018-10-12 泰莱托恩基金会 miR-204和miR-211及其用途
WO2014160129A2 (en) * 2013-03-14 2014-10-02 Alnylam Pharmaceuticals, Inc. Complement component c5 irna compositions and methods of use thereof
US10144933B2 (en) 2014-01-15 2018-12-04 Shin Nippon Biomedical Laboratories, Ltd. Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator
JPWO2015108046A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗アレルギー作用を有するキラル核酸アジュバンド及び抗アレルギー剤
JPWO2015108048A1 (ja) 2014-01-15 2017-03-23 株式会社新日本科学 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤
EP4137572A1 (en) 2014-01-16 2023-02-22 Wave Life Sciences Ltd. Chiral design
EP3191591A1 (en) 2014-09-12 2017-07-19 Alnylam Pharmaceuticals, Inc. Polynucleotide agents targeting complement component c5 and methods of use thereof
EP3277811B1 (en) 2015-04-03 2020-12-23 University of Massachusetts Fully stabilized asymmetric sirna
CA2995110A1 (en) 2015-08-14 2017-02-23 University Of Massachusetts Bioactive conjugates for oligonucleotide delivery
MA44908A (fr) 2015-09-08 2018-07-18 Sylentis Sau Molécules d'arnsi et leur utilisation dans des procédés et des compositions pour inhiber l'expression du gène nrarp
EP3487507A4 (en) * 2016-07-21 2020-04-08 American Gene Technologies International, Inc. VIRAL VECTORS FOR THE TREATMENT OF PARKINSON'S DISEASE
CN109890964A (zh) * 2016-09-09 2019-06-14 康奈尔大学 核酸、蛋白和小分子在玻璃体囊泡体中的递送
US20180092776A1 (en) 2016-09-30 2018-04-05 Sara Heikali Method and device for treating and managing diseased ocular tissue
KR20190077471A (ko) * 2016-11-02 2019-07-03 프리드리히 미셔 인스티튜트 포 바이오메디칼 리서치 방향 선택적인 망막 신경절 세포에서의 유전자의 특이적 발현을 위한 프로모터, synp198
RU2633349C1 (ru) * 2016-11-24 2017-10-11 Федеральное государственное автономное учреждение "Межотраслевой научно-технический комплекс "Микрохирургия глаза" имени академика С.Н. Федорова" Министерства здравоохранения Российской Федерации Способ определения дифференцированных показаний к срокам лечения нарушений прекорнеальной слезной пленки после лазерного in situ кератомилеза с фемтолазерным сопровождением у детей
EP3548005A4 (en) 2016-11-29 2020-06-17 Puretech Health LLC Exosomes for delivery of therapeutic agents
RU2643579C1 (ru) * 2017-03-29 2018-02-02 Федеральное государственное автономное образовательное учреждение высшего образования "Белгородский государственный национальный исследовательский университет" (НИУ "БелГУ") Способ профилактики ишемической нейропатии зрительного нерва карбамилированным дарбэпоэтином в эксперименте
CA3064590A1 (en) 2017-06-23 2018-12-27 University Of Massachusetts Two-tailed self-delivering sirna and related methods
AU2018360697A1 (en) 2017-11-01 2020-05-14 Alnylam Pharmaceuticals, Inc. Complement component C3 iRNA compositions and methods of use thereof
CN110604811B (zh) * 2018-06-14 2023-01-31 陕西慧康生物科技有限责任公司 含有重组人溶菌酶和重组人表皮生长因子的人工泪液
CA3103740A1 (en) 2018-06-29 2020-01-02 Wuhan Neurophth Biotechnology Limited Company Compositions and methods for treating leber's hereditary optic neuropathy
EP3840785A4 (en) * 2018-08-20 2022-07-13 Wuhan Neurophth Biotechnology Limited Company COMPOSITIONS AND METHODS FOR THE TREATMENT OF LEBERIAN OPTIC ATROPHY
JP7627042B2 (ja) 2018-08-23 2025-02-05 ユニバーシティー オブ マサチューセッツ Ｏ－メチルリッチ完全安定化オリゴヌクレオチド
EP3852608A4 (en) 2018-09-21 2022-09-28 Aufbau Medical Innovations Limited COMPOSITIONS AND METHODS FOR TREATING GLAUCOMA
CN113614232A (zh) 2019-01-18 2021-11-05 马萨诸塞大学 动态药代动力学修饰锚
EP3914205A4 (en) * 2019-01-22 2022-09-14 The Board of Trustees of the Leland Stanford Junior University SILICONE OIL INDUCED HYPERPRESSURE AND GLAUCOMA MODEL
US12024706B2 (en) 2019-08-09 2024-07-02 University Of Massachusetts Modified oligonucleotides targeting SNPs
US12365894B2 (en) 2019-09-16 2025-07-22 University Of Massachusetts Branched lipid conjugates of siRNA for specific tissue delivery
JP7676377B2 (ja) 2019-10-22 2025-05-14 アルナイラム ファーマシューティカルズ， インコーポレイテッド 補体成分Ｃ３ ｉＲＮＡ組成物およびその使用方法
JP2021080253A (ja) * 2019-11-19 2021-05-27 ジョンソン・アンド・ジョンソン・コンシューマー・インコーポレイテッドＪｏｈｎｓｏｎ ＆ Ｊｏｈｎｓｏｎ Ｃｏｎｓｕｍｅｒ Ｉｎｃ． 眼を治療するための組成物及び方法
US11969451B2 (en) 2019-11-19 2024-04-30 Johnson & Johnson Surgical Vision, Inc. Compositions and methods for treating the eye
CN113025633B (zh) 2019-12-09 2024-08-27 武汉纽福斯生物科技有限公司 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用
US11400039B2 (en) * 2020-01-16 2022-08-02 James W. Hill Changing eye color by gene transduction
CN112063624A (zh) * 2020-09-19 2020-12-11 湖南中医药大学 一种抑制caspase 1基因表达的siRNA分子及其应用
JP7536187B2 (ja) 2021-04-19 2024-08-19 ノヴォ ノルディスク アー／エス 核内受容体サブファミリー１グループｈメンバー３（ｎｒ１ｈ３）発現を阻害するための組成物および方法
WO2023014654A2 (en) * 2021-08-02 2023-02-09 University Of Massachusetts Oligonucleotides for htt-1a modulation
EP4423273A1 (en) 2021-10-29 2024-09-04 Alnylam Pharmaceuticals, Inc. Complement factor b (cfb) irna compositions and methods of use thereof
CN116548384A (zh) * 2023-04-12 2023-08-08 电子科技大学 一种青光眼干预疾病模型的构建方法
EP4560020A1 (en) 2023-11-22 2025-05-28 Sylentis S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions
EP4560019A1 (en) 2023-11-22 2025-05-28 Sylentis S.A.U. Sirna and compositions for prophylactic and therapeutic treatment of ocular retinal conditions

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6251666B1 (en) * 1997-03-31 2001-06-26 Ribozyme Pharmaceuticals, Inc. Nucleic acid catalysts comprising L-nucleotide analogs
AU2001289068A1 (en) * 2000-09-20 2002-04-02 Isis Pharmaceuticals, Inc. Antisense modulation of caspase 2 expression
US20060217331A1 (en) * 2001-05-18 2006-09-28 Sirna Therapeutics, Inc. Chemically modified double stranded nucleic acid molecules that mediate RNA interference
US20050282188A1 (en) * 2001-05-18 2005-12-22 Sirna Therapeutics, Inc. RNA interference mediated inhibition of gene expression using short interfering nucleic acid (siNA)
WO2004033620A2 (en) * 2001-11-02 2004-04-22 Insert Therapeutics, Inc. Methods and compositions for therapeutic use of rna interference
PT1527176E (pt) * 2002-08-05 2007-04-30 Atugen Ag Novas formas de muléculas de arn de interferência
NZ542665A (en) * 2003-03-05 2008-05-30 Senesco Technologies Inc Use of antisense oligonucleotides or siRNA to suppress expression of eIF-5A1
US20060241034A1 (en) * 2003-05-22 2006-10-26 David Chauvier Means for preventing and treating cellular death and their biological applications
FR2855054B1 (fr) * 2003-05-22 2005-07-08 Theraptosis Moyens pour bloquer ou retarder une mort cellulaire in vitro
CA2577423C (en) * 2004-08-16 2012-11-06 Quark Biotech, Inc. Therapeutic uses of inhibitors of rtp801
TW200639253A (en) * 2005-02-01 2006-11-16 Alcon Inc RNAi-mediated inhibition of ocular targets
JP2010507387A (ja) * 2006-10-25 2010-03-11 クアーク・ファーマスーティカルス、インコーポレイテッド 新規のｓｉＲＮＡおよびその使用方法
US20100292301A1 (en) 2007-02-28 2010-11-18 Elena Feinstein Novel sirna structures
US8614309B2 (en) * 2007-10-03 2013-12-24 Quark Pharmaceuticals, Inc. Double-stranded RNA directed to CASP2 and methods of use thereof
KR101672563B1 (ko) * 2008-10-22 2016-11-03 쿠아크 파마수티칼스 인코퍼레이티드 안질환을 치료하는 방법

Also Published As

Publication number Publication date
US20170306329A1 (en) 2017-10-26
JP2012506450A (ja) 2012-03-15
WO2010048352A3 (en) 2010-06-17
KR20110081826A (ko) 2011-07-14
US20150050328A1 (en) 2015-02-19
NZ591391A (en) 2012-10-26
CA2738957A1 (en) 2010-04-29
KR101672563B1 (ko) 2016-11-03
EP2350279A2 (en) 2011-08-03
ES2563984T3 (es) 2016-03-17
IL212986A0 (en) 2011-07-31
EA022418B1 (ru) 2015-12-30
AU2009308380B2 (en) 2015-05-28
CN104857526A (zh) 2015-08-26
EP2350279B1 (en) 2016-01-27
US8765931B2 (en) 2014-07-01
US9701961B2 (en) 2017-07-11
CN102994500B (zh) 2015-04-01
DK2350279T3 (en) 2016-02-15
US20150361430A1 (en) 2015-12-17
WO2010048352A2 (en) 2010-04-29
PL2350279T3 (pl) 2016-05-31
CN102994500A (zh) 2013-03-27
CA2962219C (en) 2020-08-25
US20110229557A1 (en) 2011-09-22
AU2009308380A1 (en) 2010-04-29
HK1183693A1 (en) 2014-01-03
IL212986A (en) 2016-05-31
CN102449151A (zh) 2012-05-09
WO2010048352A8 (en) 2011-08-11
JP5592892B2 (ja) 2014-09-17
EA201170551A1 (ru) 2011-12-30
CA2962219A1 (en) 2010-04-29
HK1212883A1 (zh) 2016-06-24
US9121020B2 (en) 2015-09-01
CN104857526B (zh) 2019-03-05

Similar Documents

Publication Publication Date Title
IL212986A0 (en) Methods for treating eye disorders
IL257418A (en) Methods for treating addiction
GB2467710B (en) Methods for treating social disorders
WO2010144865A9 (en) Methods for treating gastrointestinal disorders
EP2331088A4 (en) COMPOSITIONS AND METHODS FOR TREATING PSYCHIATRIC ILLNESSES
IL212404A0 (en) Compounds for treating ophthalmic diseases and disorders
IL212348A0 (en) Treatment method
PL2635299T3 (pl) Sposoby leczenia zaburzeń utraty włosów
IL186895A0 (en) Methods for treating eye conditions
EP2355739A4 (en) EYE THERAPY SYSTEM
EP2346457A4 (en) EYE THERAPY SYSTEM
EP2346429A4 (en) OCULAR THERAPY SYSTEM
IL208069A0 (en) Methods for treating psoriasis
IL249528B (en) involved in the treatment of damaged marrow tissue
GB0915259D0 (en) Sulphur-linked compounds for treating ophthalmic diseases and disorders
EP2331097A4 (en) METHOD FOR TREATING CNS DISEASES
EP2477635A4 (en) METHODS OF TREATING CEREBRAL TUMORS
EP2296682B8 (en) Methods of treating ophthalmic disorders
ZA201009226B (en) Nifurtimox for treating disease caused by trichomonadida
SG10201401310VA (en) Method for treating immune disorders
EP2387402A4 (en) METHOD FOR THE TREATMENT OF INFLAMMATORY DISORDERS WITH 2,4-PYRIMIDINIAMIN COMPOUNDS
EP2296461A4 (en) METHODS OF TREATING ARTHROPODS
IL207906A0 (en) Treatment for ocular-related disorders
EP2341860A4 (en) EYE THERAPY SYSTEM
ZA200801796B (en) Methods for treating substance-related disorders